Tweeter button Delicious button Digg button Stumbleupon button
Monthly Archives: January 2014
Fatty Liver Disease | Preclinical Study Demonstrates Effect Of Galectin Inhibitor On Serum Biomarker In Fatty Liver Disease With Fibrosis

As previously reported and published in PLOS ONE, the same study showed that GR-MD-02 improved all components of NASH in mice, including fibrosis [ ].GR-MD-02 is a proprietary molecule that binds to and inhibits galectin proteins, predominantly galectin-3. Patient enrollment is complete in cohort 1 of a blinded Phase 1 clinical trial of GR-MD-02 for patients with NASH with advanced fibrosis. No    .. more …

Facebook Twitter Email

Cirrhosis | Magic Wand That Spots If You've Been Overdoing It: Pen-like Device Can Detect Cirrhosis Of The Liver

By Thea Jourdan PUBLISHED: 19:11 EST, 27 January 2014 A new diagnostic device based on an instrument used to check the ripeness of cheese can detect cirrhosis of the liver. It does this earlier and with greater reliability than current tests, potentially saving thousands of lives. Each year in England, around 12,000 people die from cirrhosis, or scarring of the liver. A third of those deaths    .. more …

Facebook Twitter Email

Posted on January 28, 2014, 8:10 pm By
Categories: cirrhosis Tags:
Fatty Liver Disease | Research And Markets: Fatty Liver Disease Global Clinical Trials Review, H2 2013: Profiles Players Such As Biovil …

DUBLIN–(BUSINESS WIRE)– Research and Markets ( ) has announced the addition of the “Fatty Liver Disease Global Clinical Trials Review, H2, 2013″ report to their offering. The clinical trial report, Fatty Liver Disease Global Clinical Trials Review, H2, 2013” provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the    .. more …

Facebook Twitter Email

Liver Cancer | Sirtex Medical Inc. Reports 23.7 Percent Dose Sales Growth Of SIR-Spheres Microspheres In Second Quarter

WOBURN, Mass.–(BUSINESS WIRE)– Sirtex Medical Inc. , a subsidiary of Sirtex Medical Limited ( SRX.AX ), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced that second quarter dose sales of SIR-Spheres microspheres grew 23.7 percent in the Americas region compared to the previous corresponding period for the quarter ending December 31, 2013. “The Americas    .. more …

Facebook Twitter Email

Important Disclaimer: Article Comments provided are for general information purposes only and are not intended to substitute for informed professional medical, psychological, tax, accounting, legal, investment, or any other professional advice. We expressly disclaim liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in these comments or anywhere else within the site. Lastly, we do not endorse any article or comment. Use at your own risk.